NCT07126990View on ClinicalTrials.gov

Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

August 30, 2028

Study Completion Date

August 30, 2028

Conditions
Glioma
Interventions
BIOLOGICAL

Novel oncolytic virus Ad-TD-nsIL12

Ommaya capsule was placed for intratumoral injection at a dose of 1×10\^10vp

Trial Locations (1)

Unknown

Sanbo Brain Hospital, Capital Medical University, Beijing, Haidian District, Beijing

All Listed Sponsors
collaborator

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

INDUSTRY

lead

Xiaorong Wu

INDUSTRY